How much profit has IGC Pharma made this year?
IGC Pharma has made -8.52 M USD this year.
IGC Pharma Net Income 2025
IGC Pharma Net Income
-8.52 M USD
Ticker
IGC
ISIN
US45408X3089
WKN
A1T87A
In 2025, IGC Pharma's profit amounted to -8.52 M USD, a -34.5% increase from the -13 M USD profit recorded in the previous year.
The IGC Pharma Net Income history
| YEAR | NET INCOME (undefined USD) |
|---|---|
| 2027e | -9.39 |
| 2026e | -8.12 |
| 2025e | -8.52 |
| 2024 | -13 |
| 2023 | -11.51 |
| 2022 | -15.02 |
| 2021 | -8.81 |
| 2020 | -7.32 |
| 2019 | -4.1 |
| 2018 | -1.79 |
| 2017 | -1.87 |
| 2016 | -2.81 |
| 2015 | -4.61 |
| 2014 | -3.02 |
| 2013 | -2.25 |
| 2012 | -7.75 |
| 2011 | -20.24 |
| 2010 | -4.79 |
| 2009 | -0.52 |
| 2008 | -5.22 |
| 2007 | 1.52 |
| 2006 | -0.44 |
IGC Pharma Revenue, EBIT, Net Income US45408X3089 · A1T87A
3 years
5 years
10 years
25 Years
Max
Revenue
EBIT
Net Income
Details
Revenue, EBIT and Profit
ⓘUnderstanding Revenue, EBIT, and Income
Gain insights into IGC Pharma, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by IGC Pharma from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects IGC Pharma’s net earnings, an ultimate measure of its financial health and profitability.
Yearly Analysis and Comparisons
Observe the yearly bars to understand the annual performance and growth of IGC Pharma. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.
Utilizing Expectations for Investment
The expected values for the forthcoming years offer investors a glimpse into IGC Pharma’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.
Investment Insights
Leveraging the comparison between Revenue and EBIT helps in assessing IGC Pharma’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on IGC Pharma’s growth potential.
IGC Pharma Revenue, EBIT and net profit per share
| Date | IGC Pharma Revenue | IGC Pharma EBIT | IGC Pharma Net Income |
|---|---|---|---|
| 2027e | 1.52 M undefined | -12.8 M undefined | -9.39 M undefined |
| 2026e | 1.36 M undefined | -10.75 M undefined | -8.12 M undefined |
| 2025e | 1.2 M undefined | -9.96 M undefined | -8.52 M undefined |
| 2024 | 1.35 M undefined | -8.8 M undefined | -13 M undefined |
| 2023 | 910,000 undefined | -11.19 M undefined | -11.51 M undefined |
| 2022 | 400,000 undefined | -10.68 M undefined | -15.02 M undefined |
| 2021 | 900,000 undefined | -8.72 M undefined | -8.81 M undefined |
| 2020 | 4.07 M undefined | -6.87 M undefined | -7.32 M undefined |
| 2019 | 5.12 M undefined | -4.64 M undefined | -4.1 M undefined |
| 2018 | 2.19 M undefined | -1.79 M undefined | -1.79 M undefined |
| 2017 | 580,000 undefined | -2.05 M undefined | -1.87 M undefined |
| 2016 | 6.37 M undefined | -2.59 M undefined | -2.81 M undefined |
| 2015 | 7.68 M undefined | -4.34 M undefined | -4.61 M undefined |
| 2014 | 2.27 M undefined | -2.51 M undefined | -3.02 M undefined |
| 2013 | 8.03 M undefined | -2.18 M undefined | -2.25 M undefined |
| 2012 | 4.2 M undefined | -6.32 M undefined | -7.75 M undefined |
| 2011 | 4.07 M undefined | -7.91 M undefined | -20.24 M undefined |
| 2010 | 17.9 M undefined | -3.99 M undefined | -4.79 M undefined |
| 2009 | 35.34 M undefined | 2.31 M undefined | -520,000 undefined |
| 2008 | 2.19 M undefined | -20,000 undefined | -5.22 M undefined |
| 2007 | 0 undefined | 0 undefined | 1.52 M undefined |
| 2006 | 0 undefined | -530,000 undefined | -440,000 undefined |
| Revenue | EBIT | Net Income | |
|---|---|---|---|
| 2006 | 0 USD | -530,000 USD | -440,000 USD |
| 2007 | 0 USD | 0 USD | 1.52 M USD |
| 2008 | 2.19 M USD | -20,000 USD | -5.22 M USD |
| 2009 | 35.34 M USD | 2.31 M USD | -520,000 USD |
| 2010 | 17.9 M USD | -3.99 M USD | -4.79 M USD |
| 2011 | 4.07 M USD | -7.91 M USD | -20.24 M USD |
| 2012 | 4.2 M USD | -6.32 M USD | -7.75 M USD |
| 2013 | 8.03 M USD | -2.18 M USD | -2.25 M USD |
| 2014 | 2.27 M USD | -2.51 M USD | -3.02 M USD |
| 2015 | 7.68 M USD | -4.34 M USD | -4.61 M USD |
| 2016 | 6.37 M USD | -2.59 M USD | -2.81 M USD |
| 2017 | 580,000 USD | -2.05 M USD | -1.87 M USD |
| 2018 | 2.19 M USD | -1.79 M USD | -1.79 M USD |
| 2019 | 5.12 M USD | -4.64 M USD | -4.1 M USD |
| 2020 | 4.07 M USD | -6.87 M USD | -7.32 M USD |
| 2021 | 900,000 USD | -8.72 M USD | -8.81 M USD |
| 2022 | 400,000 USD | -10.68 M USD | -15.02 M USD |
| 2023 | 910,000 USD | -11.19 M USD | -11.51 M USD |
| 2024 | 1.35 M USD | -8.8 M USD | -13 M USD |
| 2025e | 1.2 M USD | -9.96 M USD | -8.52 M USD |
| 2026e | 1.36 M USD | -10.75 M USD | -8.12 M USD |
| 2027e | 1.52 M USD | -12.8 M USD | -9.39 M USD |
IGC Pharma stock margins US45408X3089 · A1T87A
The IGC Pharma margin analysis displays the gross margin, EBIT margin, as well as the profit margin of IGC Pharma. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for IGC Pharma.
3 years
5 years
10 years
25 Years
Max
Gross margin
EBIT margin
Profit margin
Details
Margin
ⓘUnderstanding Gross Margin
The gross margin, expressed as a percentage, delineates the gross profit made from the IGC Pharma's sales revenue. A higher gross margin percentage indicates that the IGC Pharma retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.
EBIT Margin Analysis
EBIT margin represents the IGC Pharma's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.
Revenue Margin Insights
The revenue margin demonstrates the IGC Pharma's total revenue generated. When comparing the revenue margin year over year, investors can gauge the IGC Pharma's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.
Interpreting Expectations
The expected values for gross, EBIT, and revenue margins provide future financial outlook of the IGC Pharma. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.
Comparative Analysis
Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the IGC Pharma's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.
IGC Pharma Margin History
| IGC Pharma Gross margin | IGC Pharma Profit margin | IGC Pharma EBIT margin | IGC Pharma Profit margin |
|---|---|---|---|
| 2027e | 54.5 % | -845 % | -619.6 % |
| 2026e | 54.5 % | -787.82 % | -595.63 % |
| 2025e | 54.5 % | -828.11 % | -707.86 % |
| 2024 | 54.5 % | -654.13 % | -966.54 % |
| 2023 | 48.35 % | -1,229.67 % | -1,264.84 % |
| 2022 | 47.5 % | -2,670 % | -3,755 % |
| 2021 | 12.22 % | -968.89 % | -978.89 % |
| 2020 | 2.95 % | -168.8 % | -179.85 % |
| 2019 | 2.54 % | -90.63 % | -80.08 % |
| 2018 | 3.65 % | -81.74 % | -81.74 % |
| 2017 | 37.93 % | -353.45 % | -322.41 % |
| 2016 | 13.19 % | -40.66 % | -44.11 % |
| 2015 | 7.55 % | -56.51 % | -60.03 % |
| 2014 | 16.74 % | -110.57 % | -133.04 % |
| 2013 | 19.05 % | -27.15 % | -28.02 % |
| 2012 | -14.76 % | -150.48 % | -184.52 % |
| 2011 | 3.93 % | -194.35 % | -497.3 % |
| 2010 | 12.46 % | -22.29 % | -26.76 % |
| 2009 | 23.09 % | 6.54 % | -1.47 % |
| 2008 | 18.72 % | -0.91 % | -238.36 % |
| 2007 | 54.5 % | 0 % | 0 % |
| 2006 | 54.5 % | 0 % | 0 % |
| Gross margin | EBIT margin | Profit margin | |
|---|---|---|---|
| 2006 | 54.5 % | 0 % | 0 % |
| 2007 | 54.5 % | 0 % | 0 % |
| 2008 | 18.72 % | -0.91 % | -238.36 % |
| 2009 | 23.09 % | 6.54 % | -1.47 % |
| 2010 | 12.46 % | -22.29 % | -26.76 % |
| 2011 | 3.93 % | -194.35 % | -497.3 % |
| 2012 | -14.76 % | -150.48 % | -184.52 % |
| 2013 | 19.05 % | -27.15 % | -28.02 % |
| 2014 | 16.74 % | -110.57 % | -133.04 % |
| 2015 | 7.55 % | -56.51 % | -60.03 % |
| 2016 | 13.19 % | -40.66 % | -44.11 % |
| 2017 | 37.93 % | -353.45 % | -322.41 % |
| 2018 | 3.65 % | -81.74 % | -81.74 % |
| 2019 | 2.54 % | -90.63 % | -80.08 % |
| 2020 | 2.95 % | -168.8 % | -179.85 % |
| 2021 | 12.22 % | -968.89 % | -978.89 % |
| 2022 | 47.5 % | -2,670 % | -3,755 % |
| 2023 | 48.35 % | -1,229.67 % | -1,264.84 % |
| 2024 | 54.5 % | -654.13 % | -966.54 % |
| 2025e | 54.5 % | -828.11 % | -707.86 % |
| 2026e | 54.5 % | -787.82 % | -595.63 % |
| 2027e | 54.5 % | -845 % | -619.6 % |
IGC Pharma Aktienanalyse
What does IGC Pharma do?
India Globalization Capital Inc. (IGC) is a Maryland-based company that focuses on the development, marketing, and sale of natural supplements, novel cannabis formulations, food and beverages, and the manufacturing of medical devices. IGC was established in 2005 and initially operated as a construction company in India. However, over the years, the company has evolved into a diversified company based in Maryland due to its innovative products and services. One of IGC's most well-known divisions is IGC Pharma, which focuses on cannabis-based medical formulations and medical devices. IGC holds patent applications for certain cannabis-based products and was one of the first companies to explore the use of cannabis as a potential treatment for Alzheimer's patients. In collaboration with the Institute for Medicine and the Origins of Infancy at the University of Maryland, IGC developed a novel THC-based medication for the treatment of spasms, pain, and other symptoms in multiple sclerosis patients. IGC has also developed the "Hyalolex" product, which is made from specific cannabinoids such as CBD. This preparation is available in Germany under the trade name "Cannabidiol Hexal." Hyalolex is available as a dietary supplement and has been proven effective in improving memory performance, attention, and cognitive abilities in Alzheimer's patients. IGC also operates the IGC Nutraceuticals division, which focuses on the manufacturing and marketing of high-quality natural products. These include vitamins, minerals, dietary supplements, and natural herbal supplements that promote physical and mental well-being and support healthy bodily processes. Some of IGC Nutraceuticals' products include Saffron for Depression Relief, the calcium and magnesium formulation, and Bharat Diagnostics. IGC will continue to invest in various fields, including cannabis-based pain relief, dementia treatments, electrochemical energy storage, and the manufacturing of devices that utilize natural resources such as coal and ore. Overall, IGC has become a diversified company that focuses on a variety of industries. IGC has been a pioneer in the cannabis industry and has gained a good reputation through innovative formulations and patents. By expanding into new industries and investing in new technologies, IGC will continue to stay at the forefront of innovation and strengthen its position as one of the emerging development companies in today's economy. IGC Pharma ist eines der beliebtesten Unternehmen auf Eulerpool.com.Net Income Details
Understanding IGC Pharma's Profit Margins
The profit margins of IGC Pharma represent the net income earned after deducting all operational expenses, costs, and taxes from the revenue. This figure is a clear indicator of IGC Pharma's financial health, operational efficiency, and profitability. Higher profit margins signify better cost management and income generation capabilities.
Year-to-Year Comparison
Evaluating IGC Pharma's profit on a yearly basis can offer significant insights into its financial growth, stability, and trends. A consistent increase in profit suggests improved operational efficiency, cost management, or increased revenue, while a decrease may indicate rising costs, declining sales, or operational challenges.
Impact on Investments
IGC Pharma's profit figures are critical for investors who are aiming to understand the company's financial standing and future growth prospects. Increased profits often lead to higher stock valuations, boosting investor confidence and attracting more investments.
Interpreting Profit Fluctuations
When IGC Pharma’s profit increases, it often indicates enhanced operational efficiency or increased sales. In contrast, a decline in profit can signal operational inefficiencies, increased costs, or competitive pressures, necessitating strategic interventions to boost profitability.
Frequently Asked Questions about IGC Pharma stock
How has the profit developed compared to last year?
The profit has increased by -34.5% compared to last year fallen
What impact do the earnings have on the shareholders?
An increase in earnings is usually seen as a positive indicator for shareholders as it means that the company is generating profits.
How does IGC Pharma publish its earnings?
IGC Pharma publishes its earnings in the form of quarterly or annual reports.
Which financial indicators are included in the quarterly or annual reports?
The quarterly or annual reports contain information about sales and profit, cash flow, balance sheet, and other fundamentals.
Why is it important for investors to know the earnings of IGC Pharma?
The profits of IGC Pharma are an important indicator of the financial health of the company and can help investors decide whether they want to invest in the company or not.
How can one learn more about the earnings of IGC Pharma?
You can learn more about the earnings of IGC Pharma by reviewing the quarterly or annual reports or following the company presentations.
How much dividend does IGC Pharma pay?
Over the past 12 months, IGC Pharma paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, IGC Pharma is expected to pay a dividend of 0 USD.
What is the dividend yield of IGC Pharma?
The current dividend yield of IGC Pharma is .
When does IGC Pharma pay dividends?
IGC Pharma pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of IGC Pharma?
IGC Pharma paid dividends every year for the past 0 years.
What is the dividend of IGC Pharma?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is IGC Pharma located?
IGC Pharma is assigned to the 'Industry' sector.
Wann musste ich die Aktien von IGC Pharma kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of IGC Pharma from 1/18/2025 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 1/18/2025.
When did IGC Pharma pay the last dividend?
The last dividend was paid out on 1/18/2025.
What was the dividend of IGC Pharma in the year 2024?
In the year 2024, IGC Pharma distributed 0 USD as dividends.
In which currency does IGC Pharma pay out the dividend?
The dividends of IGC Pharma are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
The IGC Pharma stock can be added to a savings plan with the following providers: Trade Republic
Andere Kennzahlen von IGC Pharma
Our stock analysis for IGC Pharma Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of IGC Pharma Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
